title: [A Retrospective Study of Ph Negative Adolescent and Young Adults with Acute B Lymphoblastic Leukemia in Two Centers].
abstract: OBJECTIVE
  To analyze the therapeutic efficacy of different consolidation therapies after induction remission on Ph negative adolescent and young adults with acute B lymphoblastic leukemia, and to explore the effect of different risk factors on prognosis.
  
  
  METHODS
  The treatment and efficacy of 80 Ph negative B-ALL in patients of 16-39 years old in the Hematology Department of 301(65 cases) and 309(15 cases) hospital from 1999 to 2016 are retrospectively analyzed. The patients received combined induction chemotherapy of 4 or 5 chemotherapeutic drugs (VDCLP/ VDLP/ DOLP/ IOLP). After remission patients received consolidation protocols of 3-5 cycls, and then received allo-HSCT or haploidentical HSCT. The median follow-up time was 29 (6-153) months.
  
  
  RESULTS
  HSCT was carried out after CR1. The 5-year OS and EFS of allo-HSCT group(n=29) was (73±16)% and (67±17)%, respectively, while those of haploidentical-HSCT group(n=20) were (53±22)% and (53±22)%, respectively, and those of pediatric-inspired protocols(n=31) was (63±17)% and (50±18)%, respectively. The difference between OS and EFS in 3 group was not statistically significant(P>0.05). The re-remission rate of recurrent patients was (50±23)%. On the one side, the cumulative incidence of TRM of pediatric-inspired protocol was better than that of HSCT (P<0.05). On the other side, the cummulative incidence of relapse (CIR) of pediatric-inspired protocol was poorer than that of HSCT, yet without significant difference (P>0.05). The median remission time of CR2 in patients was 14(2-36) months. Univariate and multivariate analysis were performed in 65 patients, and showed an abnormal result of CD13 or CD33 positive, CD22 negative, indicating a poor prognosis(P<0.05).
  
  
  CONCLUSIONS
  In the adolescent and young adult patients with Ph-B-ALL treated by pediatric-inspired protocols, the survival time is similar with that in allo-HSCT group. However, more prospective clinical studies of random control test(RCT) should be carried out.
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Hong-Hao
authors.initials: HH
authors.lastname: Gao
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Jing
authors.affiliation: Department of Hematology of Chinese PLA 309 Hospital, Beijing 100091, China.
authors.forename: Ming-Juan
authors.initials: MJ
authors.lastname: Liu
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Hong-Hua
authors.initials: HH
authors.lastname: Li
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Wen-Rong
authors.initials: WR
authors.lastname: Huang
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Chun-Ji
authors.initials: CJ
authors.lastname: Gao
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Dai-Hong
authors.initials: DH
authors.lastname: Liu
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Yong-Hui
authors.initials: YH
authors.lastname: Li
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Sai
authors.initials: S
authors.lastname: Huang
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Hematology of Chinese PLA 309 Hospital, Beijing 100091, China.
authors.forename: Yong-Qing
authors.initials: YQ
authors.lastname: Zhang
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China. E-mail: chunhuiliyu@ yahoo.com.
authors.forename: Li
authors.initials: L
authors.lastname: Yu
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D060828:Induction Chemotherapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D051918:Sialic Acid Binding Ig-like Lectin 2; D055815:Young Adult
chemical_list: C497867:CD22 protein, human; D051918:Sialic Acid Binding Ig-like Lectin 2